Related Experiment Video
Updated: Sep 11, 2026
Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
Therapeutic drug monitoring: antiarrhythmic drugs
1Department of Medicine, University of New South Wales and St Vincent's Hospital, Darlinghurst, NSW 2010, Australia.
Insights
Therapeutic drug monitoring (TDM) enhances the safe administration of certain antiarrhythmic agents, particularly Class I drugs like sodium channel blockers and others such as digoxin and perhexiline. While some classes require TDM for safety, others like beta-blockers generally do not.
Area of Science:
- Pharmacology
- Cardiology
- Clinical Therapeutics
Background:
- Antiarrhythmic agents are classified using the Vaughan Williams system into four main classes.
- Class I agents block sodium channels and have significant toxicity.
- Other agents like digoxin and perhexiline also require careful administration.
Purpose of the Study:
- To review the role of therapeutic drug monitoring (TDM) in the safe administration of various antiarrhythmic agents.
- To discuss the utility of TDM across different Vaughan Williams classes and other antiarrhythmic drugs.
Main Methods:
- Review of antiarrhythmic drug classifications, focusing on the Vaughan Williams system.
- Analysis of the specific actions and toxicities of each drug class.
- Evaluation of the necessity and utility of TDM for each agent or class.
Main Results:
- Class I antiarrhythmic agents, while less used, benefit significantly from TDM for safety.
- TDM is useful for amiodarone (Class III) to monitor compliance and toxicity.
- TDM is highly valuable for digoxin and perhexiline, improving administration safety.
Conclusions:
- Therapeutic drug monitoring is crucial for enhancing the safety of specific antiarrhythmic drugs, especially Class I agents and those outside the traditional classification.
- The need for TDM varies significantly across different antiarrhythmic drug classes.
- Careful monitoring, including TDM where appropriate, is essential for optimizing antiarrhythmic therapy and patient safety.
Abstract:
Antiarrhythmic agents are traditionally classified according to Vaughan Williams into four classes of action. Class I antiarrhythmic agents include most of the drugs traditionally thought of as antiarrhythmics, and have as a common action, blockade of the fast-inward sodium channel on myocardium. These agents have a very significant toxicity, and while they are being used less, therapeutic drug monitoring (TDM) does significantly increase the safety with which they can be administered. Class II agents are antisympathetic drugs, particularly the b-adrenoceptor blockers. These are generally safe agents which do not normally require TDM. Class III antiarrhythmic agents include sotalol and amiodarone. TDM can be useful in the case of amiodarone to monitor compliance and toxicity but is generally of little value for sotalol. Class IV antiarrhythmic drugs are the calcium channel blockers verapamil and diltiazem. These are normally monitored by haemodynamic effects, rather than using TDM. Other agents which do not fall neatly into the Vaughan Williams classification include digoxin and perhexiline. TDM is very useful for monitoring the administration (and particularly the safety) of both of these agents.
More Related Videos
Related Concept Videos
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
01:16Therapeutic Drug Monitoring: Overview and Classification
01:29Therapeutic Drug Monitoring: Affecting Factors
01:26Therapeutic Drug Monitoring: Drug Analysis Methods